1. Pharmaceutical- vs Dispensary-Sourced Cannabinoids

2. This program will include a discussion of investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Cannabis Sativa

4. Cannabinoid Pharmacology

5. History of Cannabinoid Use in Medicine

6. Current Legal Status of Cannabis in the United States

7. Cannabis-Based Drugs: DEA Schedule I

8. Cannabinoid Formulations Available in Medical Marijuana Dispensaries

9. CBD Products Available in Dispensaries

10. FDA Actions Regarding CBD Medical Claims

11. Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products

12. FDA-Approved Farm for Cannabis for Research

13. FDA Regulation of Drugs

14. Routes of CBME Delivery

15. Currently Available Cannabinoid-Based Therapies With FDA-Approved Indications

16. Evidence for Efficacy of CBME Use

17. Evidence for Efficacy of CBME Use (cont)

18. Evidence for Efficacy of CBME Use (cont)

19. Cannabinoids in Epilepsy: Experimental Evidence

20. Cochrane Review of Cannabidiol in Epilepsy

21. CBD in the Treatment of Epilepsy: Early Studies

22. CBME in Epilepsy Recent Case Series and Reports With CBD

23. AEs Associated With CBME

24. Multicenter, 12-Week, Prospective, Open-Label, Purified Oral CBD Trial

25. Add-On Oral CBD Solution in Dravet Syndrome

26. Add-On Oral CBD Solution in LGS Study 1

27. Add-On Oral CBD Solution in LGS Study 2

28. Benefits of CBD Beyond Seizure Control?

29. Effects of CBD on Serum Levels of AEDs

30. Other Cannabinoids in Clinical Development for Epilepsy

31. Conclusions

32. Abbreviations

33. Abbreviations (cont)